Quantum BioPharma Announces Corporate Updates
Quantum BioPharma (NASDAQ: QNTM), a biopharmaceutical company focused on neurodegenerative and metabolic disorders treatments, has announced key corporate updates regarding equity compensation. The Board approved the grant of 32,000 restricted share units (RSUs) to three key executives, which will vest upon completion of Phase 2 MS Study data compilation.
Additionally, the company granted 98,000 stock options to directors, officers, employees, and consultants at C$24.50 per Class B Share, with immediate vesting and expiration on September 24, 2030. Both grants are subject to a four-month statutory hold period and constitute related party transactions under MI 61-101, though qualifying for exemptions from formal valuation and minority shareholder approval requirements.
Quantum BioPharma (NASDAQ: QNTM), una società biofarmaceutica focalizzata sul trattamento di disturbi neurodegenerativi e metabolici, ha annunciato aggiornamenti aziendali chiave riguardo alla compensazione azionaria. Il Consiglio ha approvato la concessione di 32.000 unità azionarie vincolate (RSU) a tre dirigenti chiave, che matureranno al completamento della messa insieme dei dati dello Studio di Fase 2 MS. Inoltre, l'azienda ha concesso 98.000 opzioni su azioni a membri del consiglio, dirigenti, dipendenti e consulenti al prezzo di C$24,50 per azione di classe B, con maturazione immediata e scadenza il 24 settembre 2030. Entrambe le concessioni sono soggette a un periodo di trattenuta statutorio di quattro mesi e costituiscono transazioni con parti correlate ai sensi di MI 61-101, pur qualificandosi per esenzioni dall'obbligo di valutazione formale e dall'approvazione degli azionisti di minoranza.
Quantum BioPharma (NASDAQ: QNTM), una empresa biofarmacéutica centrada en tratamientos para trastornos neurodegenerativos y metabólicos, ha anunciado actualizaciones corporativas clave sobre la compensación en acciones. La Junta aprobó la concesión de 32.000 unidades de acciones restringidas (RSU) a tres ejecutivos clave, que vencerán tras la compilación de los datos del Estudio de MS de Fase 2. Además, la empresa otorgó 98.000 opciones sobre acciones a directores, altos cargos, empleados y consultores a un precio de C$24,50 por acción Clase B, con consolidación inmediata y vencimiento el 24 de septiembre de 2030. Ambas asignaciones están sujetas a un periodo de retención legal de cuatro meses y constituyen transacciones con partes relacionadas conforme a MI 61-101, aunque califican para exenciones de valoración formal y aprobación de accionistas minoritarios.
Quantum BioPharma (NASDAQ: QNTM), 신경퇴행성 및 대사 장애 치료에 집중하는 생물의약 기업은 주식 보상에 관한 중요한 회사 업데이트를 발표했습니다. 이사회는 3명의 주요 임원에게 32,000주를 제한 주식단위(RSU)로 지급하기로 승인했으며, 이 RSU는 Phase 2 MS 연구 데이터 수집 완료 시 vesting됩니다. 또한 회사는 이사, 임원, 직원 및 컨설턴트에게 98,000주 옵션을 부여했으며, 클래스 B 주당 가격은 C$24.50이며 즉시 vesting되고 2030년 9월 24일에 만료됩니다. 두 건의 보상은 모두 4개월의 법정 보유 기간의 적용을 받으며 MI 61-101에 따라 관련 당사자 거래에 해당하지만, 정식 평가 및 소수 주주 승인 의무 면제 혜택에 해당합니다.
Quantum BioPharma (NASDAQ : QNTM), une société biopharmaceutique spécialisée dans les traitements des troubles neurodégénératifs et métaboliques, a annoncé des mises à jour clés concernant la rémunération en actions. Le conseil d'administration a approuvé l'attribution de 32 000 unités d'actions restreintes (RSU) à trois cadres clés, qui vestent lors de la compilation des données de l’étude MS de phase 2. De plus, l'entreprise a accordé 98 000 options d'achat d'actions à des administrateurs, dirigeants, employés et consultants à C$24,50 par action de classe B, avec un droit immédiat et une échéance au 24 septembre 2030. Les deux allocations sont soumises à une période de blocage statutaire de quatre mois et constituent des transactions avec des parties liées selon MI 61-101, bien qu'elles bénéficient d’exemptions de l’évaluation formelle et de l’approbation des actionnaires minoritaires.
Quantum BioPharma (NASDAQ: QNTM), ein biopharmazeutisches Unternehmen, das sich auf Behandlungen neurodegenerativer und metabolischer Erkrankungen konzentriert, hat wichtige unternehmensbezogene Aktualisierungen zur aktienbasierten Vergütung bekannt gegeben. Der Vorstand hat die Gewährung von 32.000 Restricted-Stock-Einheiten (RSUs) an drei führende Führungskräfte genehmigt, welche mit der Fertigstellung der Phase-2-MS-Studien-Datenverarbeitung vesten. Außerdem hat das Unternehmen 98.000 Aktienoptionen an Direktoren, Führungskräfte, Mitarbeitende und Berater zu einem Preis von C$24,50 pro Class-B-Aktie gewährt, mit sofortigem Vesting und Ablauf am 24. September 2030. Beide Zuwendungen unterliegen einer viermonatigen gesetzlichen Haltefrist und stellen Transaktionen mit verbundenen Parteien gemäß MI 61-101 dar, wobei sie von einer formellen Bewertung und der Genehmigung durch Minderheitsaktionäre befreit sein können.
Quantum BioPharma ( NASDAQ: QNTM )، شركة أدوية حيوية تركز على علاجات اضطرابات التنكس العصبي والأيضية، أعلنت عن تحديثات مؤسسية رئيسية بخصوص التعويض بالأسهم. وافق المجلس على منح 32,000 وحدة أسهم مقيدة (RSUs) لثلاثة تنفيذيين رئيسيين، والتي ستكتسب حقوقها عند اكتمال تجميع بيانات دراسة MS للمرحلة الثانية. كما منحت الشركة 98,000 خيار أسهم لمهام المدراء والضباط والموظفين والمستشارين بسعر C$24.50 للسهم من فئة B، مع الاستحقاق الفوري وانتهاء في 24 سبتمبر 2030. كلا المنحتين خاضعتان لفترة حظر قانونية مدتها أربعة أشهر وتُعدان معاملات مع أطراف ذات علاقة وفق MI 61-101، رغم أنها تستفيد من استثناءات من التقييم الرسمي وموافقة المساهمين الأقلية.
Quantum BioPharma（NASDAQ：QNTM），一家专注于神经退行性疾病和代谢疾病治疗的生物制药公司，宣布了关于股票补偿的重要公司更新。董事会批准向三名高管授予< b>32,000份限制性股票单位（RSU），该RSU将在完成二期MS研究数据汇编时归属。公司还向董事、高管、员工及顾问授予< b>98,000份股票期权，按每股< b>C$24.50（B 类股）定价，具备即时归属，期限至2030年9月24日到期。上述两项授权均受四个月的法定禁售期约束，属于MI 61-101下的关联方交易，尽管符合豁免正式估值和少数股东批准的条件。
- RSUs are performance-based, vesting tied to Phase 2 MS Study milestone achievement
- Immediate vesting of stock options provides instant alignment with shareholder interests
- Long-term option expiration date (2030) encourages long-term commitment
- Dilutive effect from potential issuance of new shares through RSUs and options
- Related party transactions involving company directors raise governance considerations
Toronto, Ontario--(Newsfile Corp. - September 26, 2025) - Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FSE: 0K91) (Upstream: QNTM) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development, today announces the following corporate updates:
Grant of Restricted Stock Units
The Company's board of directors (the "Board") authorized and approved the grant of restricted share units (each, an "RSU") pursuant to the Company's omnibus equity incentive plan (the "Equity Incentive Plan"). The Company granted 32,000 RSUs to each of Zeeshan Saeed, Anthony Durkacz and Donal Carroll (the "RSU Grant"). The RSUs granted vest upon the compilation of data which would enable the drafting of a Phase 2 MS Study.
Stock Options Grant
In addition, the Company granted 98,000 options (the "Options") to acquire Class B subordinate voting shares in the capital of the Corporation (the "Class B Shares") at C
Statutory Hold Period and Restrictions on Resale
The Options and RSUs (and any Class B Shares issuable upon their settlement or exercise) are subject to a statutory hold period of four months and one day, and were not registered under the U.S. Securities Act and are not permitted to be offered or sold within the United States absent such registration or an applicable exemption from the registration requirements therein.
Related Party Transaction
The RSU Grant and the Option Grant, as they relate to the directors of the Company, constitutes a "related party transaction", as such term is defined in Multilateral Instrument 61-101 - Protection of Minority Shareholders in Special Transactions ("MI 61-101") due to the grants to the directors, who are members of the Board, and would require the Company to receive minority shareholder approval for, and obtain a formal valuation for the subject matter of, the transaction in accordance with MI 61-101, prior to the completion of the RSU Grant and the Option Grant, as they relate to the directors of the Company. In its consideration and approval of the RSU Grant and the Option Grant, as they relate to the directors of the Company, the Board determined that the RSU Grant and the Option Grant, as they relate to the directors of the Company, were exempt from the formal valuation and minority approval requirements of MI 61-101. The Company has relied on exemptions from the formal valuation and minority shareholder approval requirements of MI 61-101 contained in respectively, sections 5.5(a) and 5.7(1)(a) of MI 61-101 in respect of related party participation in the RSU Grant and the Option Grant, as they relate to the directors of the Company, as neither the fair market value (as determined under MI 61-101) of the subject matter of, nor the fair market value of the consideration for, the transaction, insofar as it involved the related parties, exceeded
The Company did not file a material change report more than 21 days before the RSU Grant and the Option Grant, as they relate to the directors of the Company, because the details of the grants to related parties to the Company were not settled until shortly prior to the grants, and the Company wished to proceed on an expedited basis for business reasons.
About Quantum BioPharma Ltd.
Quantum BioPharma (NASDAQ: QNTM) is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. ("Lucid"), Quantum BioPharma is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. Quantum BioPharma invented unbuzzd™ and spun out its OTC version to a company, Celly Nutrition Corp. ("Celly Nutrition"), now Unbuzzd Wellness Inc., led by industry veterans. Quantum BioPharma retains ownership of
For more information visit www.quantumbiopharma.com.
Forward-Looking Information
This press release contains forward-looking statements under applicable securities laws, identified by terms like "may," "should," "anticipate," "expect," "potential," "believe," or "intend." These statements, based on assumptions and expected future events, involve risks and uncertainties that may cause actual results to differ materially from those expressed. For more details on risks, see Quantum BioPharma's filings on SEDAR+ (www.sedarplus.ca) and EDGAR (www.sec.gov). Readers should not rely unduly on these statements, as there is no assurance that plans or expectations will occur. The Company assumes no obligation to update these statements except as required by law.
The reader is urged to refer to additional information relating to Quantum BioPharma, including its annual information form, which can be located on the SEDAR+ website at www.sedarplus.ca and on the EDGAR section of the United States Securities and Exchange Commission's website at www.sec.gov for a more complete discussion of such risk factors and their potential effects.
Contacts:
Quantum BioPharma Ltd.
Zeeshan Saeed, Founder, CEO and Executive Co-Chairman of the Board
Email: Zsaeed@quantumbiopharma.com
Telephone: (833) 571-1811
Investor Relations
Investor Relations: IR@QuantumBioPharma.com
General Inquiries: info@QuantumBioPharma.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/268222
FAQ
What equity compensation did Quantum BioPharma (QNTM) announce in September 2025?
When do the QNTM RSUs granted in September 2025 vest?
What is the exercise price and expiration date for QNTM's September 2025 stock options?
Are there any restrictions on the QNTM equity grants announced in September 2025?
Why didn't QNTM require shareholder approval for these equity grants?
